Vimta Labs Limited — Updates, 24-01-2025: Press Release

Vimta Labs Limited has reported strong Q3 and nine-month financial results for FY25, highlighting a total income of ₹911 million for Q3, reflecting a 21.1% year-over-year increase. The EBITDA for the quarter reached ₹343 million, with margins improving to 37.6%, a rise of 496 basis points compared to the same quarter last year. The profit after tax (PAT) also showed substantial growth at ₹175 million, resulting in a PAT margin of 19.2%, up from 16.3% year-over-year.

The first nine months of FY25 recorded a total income of ₹2,521 million, with an EBITDA of ₹915 million and a consistent PAT margin of 19.2%, resulting in a PAT of ₹484 million. Notably, the company has recently completed the sale of its Diagnostic and Pathological services business, which is expected to allow a sharper focus on its core drug development services. The relocation of the Pune food testing lab to Nashik aims to enhance operational efficiency.

Investors should watch closely as Vimta optimizes its service offerings and navigates the integration of recent business transfers and facility expansions, suggesting a positive outlook for sustained growth and profitability.